TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32894540
Drug: Leptin (Lep)
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin (Lep) at concentrations of 5-320 ng/mL
Study: 35896277
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor–based therapy (fixed combination of perindopril and indapamide)
Study: 35896277
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor–based therapy
Study: 33871411
Drug: Real-time medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time medication monitoring (RTMM) device (Wisepill) with SMS reminders
Study: 35530564
Drug: 0.1% TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% TXA 1000 mg (10 mL) in 1 L of irrigation solution of sterile wash (glycine) during surgery
Study: 35530564
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water (placebo) in 1 L of irrigation solution of sterile wash (glycine) during surgery
Study: 33495919
Drug: Nafamostat mesylate
Normalized name: mesylate
DrugBank: Nafamostat (DB12598)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Nafamostat mesylate (NM) 20 mg
Study: 35938913
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (alteplase + endovascular treatment)
Study: 33397429
Drug: Oral Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Ivermectin at a single dose of 0.2 mg/kg for outpatient and inpatient groups.
Study: 33397429
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment regimen for mild and moderate COVID-19 plus Ivermectin.
Study: 33397429
Drug: Hydroxychloroquine sulfate
Normalized name: Hydroxychloroquine Sulfate
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine sulfate at a dose of 400 mg twice a day for the first day and 200 mg twice a day for seven subsequent days for outpatient control group.
Study: 33397429
Drug: 200/50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200/50 mg Lopinavir/Ritonavir twice a day for seven days plus five doses of 44 mcg Interferon beta-1a every other day for inpatient control group.
Study: 32011447
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine Shen-Qi Hua-Yu formula
Study: 32759183
Drug: physician choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: physician choice chemotherapy
Study: 35108791
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg for 7 days
Study: 32088664
Drug: Slow breathing
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow breathing exercise (daily training for 8 weeks)
Study: 35365371
Drug: Sodium selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium selenite (200 μg/day)
Study: 35365371
Drug: Se-enriched yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Se-enriched yeast (200 μg/day)
Study: 33443719
Drug: Probiotic supplement
Normalized name: Align Probiotic Supplement Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplement (Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07)
Study: 32732334
Drug: EarlyCDT‐Lung test
Approvals — FDA: no, EMA: no, PMDA: no
Description: EarlyCDT‐Lung test plus low‐dose CT scanning 6‐monthly for up to 2 years
Study: 32270635
Drug: Articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articular injection of sodium hyaluronate
Study: 34727277
Drug: Pre-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment group (400 mg celecoxib at 4 h before THA, 200 mg at 4 h after THA, then 200 mg every 12 h until 72 h post-operation)
Study: 32436913
Drug: Longer etching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer etching time, total-etch adhesive system, and EDTA pre-treatment of sclerotic dentin in cervical wedge-shaped defects
Study: 33217117
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg bid)
Study: 36280012
Drug: PMBE (1322
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMBE (1322 mg PMBE)
Study: 36280012
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg PMBE)
Study: 36146919
Drug: Double portion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double portion of food (e.g., double portion of banana, carrot, loaf cake, salami)
Study: 36146919
Drug: Reference portion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference portion of food (e.g., half a banana, half a large peeled carrot, a slice of loaf cake, half a salami stick)
Study: 33938674
Drug: US guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: US guided SGB with 5 mL of 0.5% bupivacaine and multimodal systemic analgesia (Group A)
Study: 33239306
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) in the ESCAPE-NA1 trial
Study: 33239306
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) in the DAWN trial
Study: 33239306
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) in the DEFUSE-3 trial
Study: 70634317
Drug: Cell treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell treatment (all groups pooled)
Study: 34142392
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa oil extract (500 mg per day for 8 weeks)
Study: 36268946
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg) and articaine (68 mg) mixture
Study: 33596969
Drug: Topical combination
Normalized name: soap TOPICAL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical combination of clonidine and pentoxifylline
Study: 34274494
Drug: COVID-19 treatments
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 treatments (specific treatments not detailed)
Study: 35844438
Drug: ERAS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERAS plus integrated traditional Chinese and Western medicine
Study: 35844438
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment and care
Study: 36194218
Drug: Cefepime 2
Normalized name: cefepime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 2 g/enmetazobactam 0.5 g
Study: 36194218
Drug: Piperacillin 4
Normalized name: piperacillin 4000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin 4 g/tazobactam 0.5 g
Study: 34274500
Drug: Balanced anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced anesthesia (volatile inhalational and intravenous agents)
Study: 35963082
Drug: Xylocaine 10%
Normalized name: Xylocaine 10% Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylocaine 10% pump spray
Study: 35005871
Drug: Novel hyaluronic
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel hyaluronic acid injectable gel with 0.3% lidocaine (test device)
Study: 35005871
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available injectable hyaluronic acid gel with 0.3% lidocaine (comparator)
Study: 33169863
Drug: Daily 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 1,000 IU vitamin D(3)
Study: 32540319
Drug: Survey on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survey on dentists' beliefs and behaviors concerning antibiotic prophylaxis (AP)
Study: 33470637
Drug: Interleukin-1 receptor
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Interleukin-1 receptor antagonism as adjunct therapy
Study: 36060517
Drug: TP (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP (docetaxel 75 mg/m², cisplatin 75 mg/m²)
Study: 36060517
Drug: TPF (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF (docetaxel 60 mg/m², cisplatin 60 mg/m², 5-fluorouracil 600 mg/m²)
Study: 33878462
Drug: Diphenhydramine Compound
Normalized name: diphenhydrAMINE compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine Compound (Diphenhydramine + Ammonium Chloride) plus standard of care
Study: 34788694
Drug: Lefamulin 150
Normalized name: lefamulin 150 MG in 15 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lefamulin 150 mg IV q12h for 5-7 days
Study: 34788694
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg IV q24h for 7 days
Study: 34788694
Drug: Lefamulin 600
Normalized name: lefamulin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lefamulin 600 mg oral q12h for 5 days
Study: 34788694
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg oral q24h for 7 days
Study: 35233731
Drug: Inhaled triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled triple therapy (once daily)
Study: 35233731
Drug: Inhaled dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dual therapy (twice daily)
Study: 32394658
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (at Baihui (GV 20), Guanyuan (CV 4), Qihai (CV 6), Fengchi (GB 20), Zusanli (ST 36), Sanyinjiao (SP 6)), once a day, 5 times as one course, with 2 days interval between each course, total of 4 courses.
Study: 32394658
Drug: Conventional chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemoradiotherapy and symptomatic treatment (control group).
Study: 34784804
Drug: Focused shockwave
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused shockwave therapy (f‐ESWT)
Study: 32466231
Drug: Taurine supplementation
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine supplementation (6 g)
Study: 32030845
Drug: Ultrasound-guided posterior
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided posterior quadratus lumborum block with 0.25% bupivacaine 0.5 mL/kg
Study: 32030845
Drug: Ultrasound-guided ilioinguinal/iliohypogastric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided ilioinguinal/iliohypogastric nerve block with 0.25% bupivacaine 0.2 mL/kg
Study: 34838980
Drug: Sarcojoint® 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarcojoint® 1 package twice a day
Study: 35357103
Drug: Insulin addition
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin addition to total nutrition admixture (TNA)
Study: 34082090
Drug: Typbar TCV®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typbar TCV® co-administered with MR and YF vaccines (Group 1)
Study: 34082090
Drug: Inactivated polio
Normalized name: Inactivated polio vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated polio vaccine (IPV) co-administered with MR and YF vaccines (Group 2)
Study: 33044710
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg Cu/kg as Cu-Lys-Glu
Study: 33044710
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg Cu/kg as Cu-Lys-Glu
Study: 33044710
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Cu/kg as Cu-Lys-Glu
Study: 33044710
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Cu/kg as Cu-Lys-Glu
Study: 33044710
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg Cu/kg as Cu-Lys-Glu (control)
Study: 32901234
Drug: Complete Care
Normalized name: Pepsodent Complete Care Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete Care toothpaste (CC; Himalaya)
Study: 36259302
Drug: Equicrestal placement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equicrestal placement of dental implants (Group I)
Study: 36259302
Drug: Subcrestal placement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcrestal placement of dental implants (Group II)
Study: 32367375
Drug: CONS (conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: CONS (conservative treatment)
Study: 36522767
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine alone
Study: 32720552
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser treatment (3 treatments at monthly intervals)
Study: 32720552
Drug: Watchful waiting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watchful waiting (no treatment)
Study: 34385236
Drug: Point-of-care (PoC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point-of-care (PoC) testing and immediate treatment of curable STIs
Study: 32954487
Drug: 800 mg/day
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/day of pharmaceutical-grade chondroitin sulfate (CS)
Study: 33926446
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine U300 (IGlar‐300)
Study: 33926446
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec U100 (IDeg‐100)
Study: 33046094
Drug: Medicines and
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medicines and Alcohol Consultation (MAC) delivered by trained community pharmacists (n=5) during Medicine Use Review (MUR) and New Medicine Service (NMS) consultations.
Study: 36002548
Drug: 1250 mg
Normalized name: bran 1250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1250 mg of β-nicotinamide mononucleotide (β-NMN) administered orally once daily for up to 4 weeks
Study: 35278903
Drug: Savlon antiseptic
Normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savlon antiseptic cream
Study: 35278903
Drug: Soap and
Normalized name: Green soap and industrial methylated spirit only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soap and water treatment
Study: 36113531
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of Cervarix
Study: 36113531
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of Cervarix
Study: 36113531
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of Cervarix
Study: 36113531
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of Gardasil-9
Study: 36113531
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of Gardasil-9
Study: 36113531
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of Gardasil-9
Study: 33072214
Drug: ProTaper Universal
Normalized name: STATLOCK UNIVERSAL PLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProTaper Universal files (Dentsply Maillefer) used in rotary preparation
Study: 33072214
Drug: Failures during
Normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Failures during rotary preparation
Study: 35501569
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment protocol (Control)
Study: 32603336
Drug: Soft tissue
Normalized name: INSULIN DETEMIR 14.2 mg in 1 mL SOFT TISSUE IMPLANT [Levemir]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft tissue therapy (STT) techniques for the masseter muscle
Study: 35723225
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (metformin/insulin/glipizide)
Study: 34684508
Drug: Wahls diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wahls diet (including supplements)
Study: 34684508
Drug: Both diets
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both diets (including supplements)
Study: 36074965
Drug: Blessed TRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blessed TRI 360TM capsule (Biofield Energy Treated Proprietary Dietary Supplement) taken twice a day (morning and evening)
Study: 36074965
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (no treatment/capsule)
Study: 36074965
Drug: Blessed TRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blessed TRI 360TM capsule
Study: 33705355
Drug: 1,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 IU daily vitamin D3 supplementation
Study: 33705355
Drug: 3,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,000 IU daily vitamin D3 supplementation
Study: 36396999
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg L-1 SiO2-NPs
Study: 36396999
Drug: SiO2-NPs treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SiO2-NPs treatment
Study: 34811384
Drug: Weekly interactive
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly interactive text messages asking 'How are you?' until 24 months postpartum.
Study: 32559503
Drug: Covariates (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Covariates (treatment group, time, baseline depression severity)
Study: 32729275
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon angioplasty (DBA)
Study: 32966683
Drug: 60 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g/d of mixed nuts (nut group)
Study: 32210455
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (1 g, 25 mg lidocaine + 25 mg prilocaine applied 1 hour prior to puncture)
Study: 32210455
Drug: Lidocaine tape
Normalized name: lidocaine Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine tape (one sheet, 18 mg lidocaine applied 30 minutes prior to puncture)
Study: 36210311
Drug: Thoracodorsal flap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracodorsal flap and implant
Study: 32213342
Drug: Subcutaneous daratumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous daratumumab (1800 mg co-formulated with 2000 U/mL recombinant human hyaluronidase PH20)
Study: 32213342
Drug: Intravenous daratumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous daratumumab (16 mg/kg)
Study: 38832105
Drug: Subcutaneous daratumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous daratumumab
Study: 32213342
Drug: Intravenous daratumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous daratumumab
Study: 32070386
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment planning
Study: 36399909
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy (six cycles of 5‐fluorouracil, leucovorin [FU/FA], oxaliplatin [FOLFOX] and panitumumab [Pmab])
Study: 36399909
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy (FU/FA plus Pmab)
Study: 36399909
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy (FU/FA alone)
Study: 33148693
Drug: Nivolumab and
Normalized name: nivolumab and relatlimab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab and ipilimumab combination therapy
Study: 35452458
Drug: Low-dose remifentanil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose remifentanil (0.25 mcg/kg/min)
Study: 35452458
Drug: High-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose remifentanil (0.5 mcg/kg/min)
Study: 35452458
Drug: Remifentanil (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (combined dosage)
Study: 32229597
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (n = 4,755)
Study: 32229597
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (n = 4,728)
Study: 36165878
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg hidden injection)
Study: 36165878
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (hidden injection)
Study: 33962579
Drug: PSMA PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSMA PET/CT prior to definitive radiation therapy (dRT)
Study: 32260313
Drug: Monopolar dielectric
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monopolar dielectric radiofrequency (MDR) treatment (8 sessions of 20 minutes each)
Study: 32260313
Drug: Sham MDR
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham MDR therapy (8 sessions of 20 minutes each)
Study: 35726109
Drug: eMBCT (web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: eMBCT (web-based mindfulness-based cognitive therapy)
Study: 32871616
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (IVI)
Study: 32871616
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (OI)
Study: 34504409
Drug: Controlled treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled treatments (no biochar)
Study: 35312188
Drug: Linear multilevel
Normalized name: Aspalathus linearis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linear multilevel treatment‐by‐covariate interaction